이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Treace Medical Concepts 관리

관리 기준 확인 2/4

Treace Medical Concepts' CEO는 John Treace, Jul2014 에 임명되었습니다 의 임기는 10.08 년입니다. 총 연간 보상은 $ 8.42M, 8.1% 로 구성됩니다. 8.1% 급여 및 91.9% 보너스(회사 주식 및 옵션 포함). 는 $ 73.08M 가치에 해당하는 회사 주식의 18.65% 직접 소유합니다. 73.08M. 경영진과 이사회의 평균 재임 기간은 각각 2.9 년과 6.6 년입니다.

주요 정보

John Treace

최고 경영자

US$8.4m

총 보상

CEO 급여 비율	8.1%
CEO 임기	10.3yrs
CEO 소유권	18.7%
경영진 평균 재임 기간	3.1yrs
이사회 평균 재임 기간	6.8yrs

최근 관리 업데이트

Recent updates

Treace Medical Concepts, Inc. (NASDAQ:TMCI) Screens Well But There Might Be A Catch

Aug 02

Treace Medical Concepts (NASDAQ:TMCI) Has Debt But No Earnings; Should You Worry?

Jun 28

Treace Medical Concepts: Facing Increasing Competitive Pressure

Jun 14

Market Still Lacking Some Conviction On Treace Medical Concepts, Inc. (NASDAQ:TMCI)

Apr 05

Does Treace Medical Concepts (NASDAQ:TMCI) Have A Healthy Balance Sheet?

Feb 09

Why Investors Shouldn't Be Surprised By Treace Medical Concepts, Inc.'s (NASDAQ:TMCI) 31% Share Price Surge

Jan 04

Market Cool On Treace Medical Concepts, Inc.'s (NASDAQ:TMCI) Revenues Pushing Shares 46% Lower

Nov 11

Analysts Are Updating Their Treace Medical Concepts, Inc. (NASDAQ:TMCI) Estimates After Its Second-Quarter Results

Aug 13

CEO 보상 분석

John Treace 의 보수는 Treace Medical Concepts 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$64m
Mar 31 2024	n/a	n/a	-US$55m
Dec 31 2023	US$8m	US$684k	-US$50m
Sep 30 2023	n/a	n/a	-US$48m
Jun 30 2023	n/a	n/a	-US$42m
Mar 31 2023	n/a	n/a	-US$47m
Dec 31 2022	US$4m	US$568k	-US$43m
Sep 30 2022	n/a	n/a	-US$45m
Jun 30 2022	n/a	n/a	-US$39m
Mar 31 2022	n/a	n/a	-US$27m
Dec 31 2021	US$688k	US$410k	-US$21m
Sep 30 2021	n/a	n/a	-US$12m
Jun 30 2021	n/a	n/a	-US$8m
Mar 31 2021	n/a	n/a	-US$5m
Dec 31 2020	US$392k	US$316k	-US$4m

보상 대 시장: John 의 총 보상 ($USD 8.42M )은 US 시장( $USD 2.41M ).

보상과 수익: 회사가 수익성이 없는 동안 John 의 보상이 증가했습니다.

CEO

John Treace (52 yo)

10.3yrs

테뉴어

US$8,422,635

보상

Mr. John T. Treace Founded Treace Medical Concepts, Inc. in 2014 and has been its Chief Executive Officer and Director since July 1, 2014. Before that, Mr. Treace served as Senior Vice President of U.S. Sa...

리더십 팀

이름	위치	테뉴어	보상	소유권
John Treace	CEO, Founder & Director	10.3yrs	US$8.42m	18.73% $ 63.5m
Mark Hair	Chief Financial Officer	4.1yrs	US$4.69m	0.031% $ 105.4k
Aaron Berutti	Senior Vice President of Sales	3.2yrs	US$3.26m	0.0066% $ 22.2k
Terry Lubben	Chief Operations & Supply Chain Officer	3.1yrs	데이터 없음	데이터 없음
Taylor Erickson	Chief Information Officer	2.6yrs	데이터 없음	데이터 없음
Scot Elder	Chief Legal & Compliance Officer and Corporate Secretary	3yrs	데이터 없음	0.0069% $ 23.3k
Nathan Minnich	Senior Vice President of Marketing	1.2yrs	데이터 없음	데이터 없음
Daniel Owens	Chief Human Resources Officer	3.7yrs	데이터 없음	0.0085% $ 28.7k
Sean Scanlan	Chief Innovation Officer	1.8yrs	데이터 없음	0.056% $ 190.1k
Shana Zink	Senior Vice President of Clinical Affairs & Reimbursement	no data	데이터 없음	데이터 없음
Rachel Osbeck	Senior Vice President of Quality Assurance & Regulatory Affairs	no data	데이터 없음	데이터 없음

3.1yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 관리: TMCI 의 관리팀은 경험 ( 2.9 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
John Treace	CEO, Founder & Director	10.3yrs	US$8.42m	18.73% $ 63.5m
Lawrence Hamilton	Independent Director	3.9yrs	US$214.79k	0.0081% $ 27.5k
James Treace	Chairman of the Board	10.3yrs	US$94.74k	2.86% $ 9.7m
Richard Mott	Independent Director	9.6yrs	US$197.26k	1.7% $ 5.8m
John Bakewell	Independent Director	3.9yrs	US$214.79k	0.77% $ 2.6m
Deepti Jain	Independent Director	3yrs	US$209.79k	0.050% $ 168.1k
Paul Dayton	Member of the Surgeon Advisory Board	no data	데이터 없음	데이터 없음
William DeCarbo	Member of the Surgeon Advisory Board	no data	데이터 없음	데이터 없음
Daniel Hatch	Member of the Surgeon Advisory Board	no data	데이터 없음	데이터 없음
J.P. McAleer	Member of the Surgeon Advisory Board	no data	데이터 없음	데이터 없음
W. Smith	Member of the Surgeon Advisory Board	no data	데이터 없음	데이터 없음
Robert Santrock	Member of the Surgeon Advisory Board	no data	데이터 없음	데이터 없음

6.8yrs

평균 재임 기간

63.5yo

평균 연령

경험이 풍부한 이사회: TMCI 의 이사회는 경험(평균 재직 기간 6.6 년)으로 간주됩니다.

Treace Medical Concepts 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

CEO, Founder & Director recently bought US$510k worth of stock

CEO, Founder & Director recently bought US$265k worth of stock

CEO, Founder & Director recently bought US$1.4m worth of stock

Treace Medical Concepts, Inc., Annual General Meeting, May 21, 2024

Treace Medical Concepts, Inc. Appoints Nathan Minnich as Senior Vice President, Marketing

Treace Medical Concepts, Inc. Appoints Julie Dewey as Chief Communications and Investor Relations Officer, Effective July 17, 2023

Recent updates

CEO, Founder & Director recently bought US$510k worth of stock

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Treace Medical Concepts, Inc. Re-Affirms Earnings Guidance for the Full Year 2024

Treace Medical Concepts, Inc. (NASDAQ:TMCI) Screens Well But There Might Be A Catch

Treace Medical Concepts, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Treace Medical Concepts (NASDAQ:TMCI) Has Debt But No Earnings; Should You Worry?

Treace Medical Concepts: Facing Increasing Competitive Pressure

CEO, Founder & Director recently bought US$265k worth of stock

CEO, Founder & Director recently bought US$1.4m worth of stock

Price target decreased by 47% to US$8.42

Treace Medical Concepts, Inc. Revises Earnings Guidance for the Full-Year 2024

New major risk - Share price stability

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Treace Medical Concepts, Inc. to Report Q1, 2024 Results on May 07, 2024

Market Still Lacking Some Conviction On Treace Medical Concepts, Inc. (NASDAQ:TMCI)

Treace Medical Concepts, Inc., Annual General Meeting, May 21, 2024

Consensus EPS estimates fall by 61%

Price target increased by 8.8% to US$15.86

Treace Medical Concepts, Inc. Provides Revenue Guidance for the Year 2024

Full year 2023 earnings: EPS misses analyst expectations

Does Treace Medical Concepts (NASDAQ:TMCI) Have A Healthy Balance Sheet?

Treace Medical Concepts, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Treace Medical Concepts, Inc. Announces Three-Year Interim Data from Its Align3d™? Post-Market Study Supporting the Use of the Lapiplasty Procedure for Treating Bunions

Why Investors Shouldn't Be Surprised By Treace Medical Concepts, Inc.'s (NASDAQ:TMCI) 31% Share Price Surge

Price target increased by 9.7% to US$14.57

Treace Medical Concepts, Inc. Revises Revenue Guidance for the Year 2023

Market Cool On Treace Medical Concepts, Inc.'s (NASDAQ:TMCI) Revenues Pushing Shares 46% Lower

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Treace Medical Concepts, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Price target decreased by 8.7% to US$25.43

Price target decreased by 11% to US$26.00

New minor risk - Share price stability

Treace Medical Concepts, Inc. Highlights New Product Innovations and Updated Align3d Clinical Study Data At the American Orthopaedic Foot & Ankle Society Annual Meeting 2023

Treace Medical Concepts, Inc. Announces Limited Market Release of New Complementary Technologies for Treating Bunions and Related Procedures

Treace Medical Concepts, Inc. Appoints Nathan Minnich as Senior Vice President, Marketing

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Treace Medical Concepts, Inc. Revises Revenue Guidance for the Year 2023

Now 26% undervalued after recent price drop

Treace Medical Concepts, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Treace Medical Concepts, Inc. Appoints Julie Dewey as Chief Communications and Investor Relations Officer, Effective July 17, 2023

Now 22% undervalued after recent price drop

Treace Medical Concepts, Inc. acquired Certain assets of MIOS Marketing, LLC dba RedPoint Medical 3D for $30 million.

Insider recently sold US$29m worth of stock

Independent Director notifies of intention to sell stock

Treace Medical Concepts, Inc. acquired Certain assets of MIOS Marketing, LLC dba RedPoint Medical 3D for $30 million.

Chief Innovation Officer exercised options and sold US$633k worth of stock

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Treace Medical Concepts, Inc. Raises Revenue Guidance for Full Year 2023

Independent Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Chief Human Resources Officer notifies of intention to sell stock

Chief Human Resources Officer notifies of intention to sell stock

CEO, Founder & Director recently sold US$51k worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Chief Innovation Officer exercised options and sold US$540k worth of stock

Treace Medical Concepts, Inc. Presents Updated ALIGN3D Interim Data and New Product Innovations at 2023 ACFAS Annual Conference

Treace Medical Concepts, Inc. has completed a Follow-on Equity Offering in the amount of $100.000005 million.

Independent Director recently sold US$480k worth of stock

Treace Medical Concepts, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Chief Human Resources Officer exercised options and sold US$82k worth of stock

Treace Receives FDA 510(k) Clearance for SpeedPlate(TM) Rapid Compression Implant Technology

Treace Medical Concepts, Inc. Receives FDA 510(K) Clearance for Speedplate Rapid Compression Implant Technology

Treace Medical Concepts, Inc. Announces First Patient Treated in MTA3D™ Adductoplasty® Clinical Study

CEO, Founder & Director recently bought US$217k worth of stock

Senior Vice President of Marketing exercised options and sold US$604k worth of stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Treace Medical Concepts, Inc. Revises Revenue Guidance for the Full Year 2022

Independent Director recently sold US$2.2m worth of stock

Treace Medical Concepts, Inc. to Report Q3, 2022 Results on Nov 08, 2022